A cohort study finds that hydroxychloroquine use in cutaneous lupus erythematosus reduces the risk of developing systemic ...

The following is a summary of “Dual seropositive nonerosive lupus arthritis: rhupus or not?” published in the February 2025 issue of Advances in Rheumatology by Pekdiker & Kara. Researchers conducted ...

Phase 1 Dose Expansion Initiated for FT819 Off-the-Shelf CAR T-cell Product Candidate with Fludarabine-free Conditioning in ...

Lupus Pleurisy about a Case in the Pneumophthisiology Department of the Ignace Deen National Hospital of the Conakry ...

Leerink Partners 2025 Global Healthcare Conference Call March 12, 2025 11:20 AM ETCompany ParticipantsRoland Chen ...

The TYK2 inhibitor deucravacitinib (Sotyktu) showed clinical potential in two diseases other than psoriasis, according to ...

Methods The electronic medical files of systemic lupus erythematosus (SLE) patients from a single tertiary rheumatology department between 2017 and 2022 were reviewed. The inclusion criteria were ...

Diagnosis of systemic lupus erythematosus meeting the 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) SLE classification criteria at least 6 months prior to ...

All SLE treatments were stopped before CAR-T cell administration ... All patients experienced drug-free remission as assessed by DORIS remission criteria and met lupus low activity state (LLDAS) ...

A majority of patients with systemic lupus erythematosus achieve prolonged remission when treated with hydroxychloroquine at ...

Systemic lupus erythematosus (SLE) is a chronic autoimmune condition that causes widespread inflammation. It can affect the skin, joints, blood vessels, and multiple organ systems. The exact cause ...

Zipalertinib pivotal Phase 2b study met primary endpoint; full results mid-year 2025 and NDA submission planned H2 2025, pending regulatory discussions Cash and investments of $606.9 million as of ...